An experimental compound tested in mice not only lowered their blood pressure but reversed structural damage already done to arteries and kidneys – something current drugs rarely accomplish. The compound, called Compound17b or Cmpd17b, targets a part of the immune system most hypertension researchers have largely overlooked: the pathway that governs the body’s ability to end its own inflammatory response.
The results, published in Communications Biology in 2026 by lead authors Dr. Jaideep Singh, Dr. Kristy L. Jackson, and Dr. Arun George Devasia, along with colleagues at Monash University and the Baker Heart and Diabetes Institute in Melbourne and collaborating institutions in Singapore, suggest that the body’s ability to shut down harmful inflammation may be as important to cardiovascular health as the blood pressure number itself.
Hypertension develops when the force of blood against artery walls remains consistently too high, and standard treatments reduce that force through several well-established mechanisms. ACE inhibitors, beta-blockers, calcium channel blockers, and thiazide diuretics each act on a different part of the pressure-regulation system. They work for millions of people – but they treat the pressure, not the tissue damage left behind.
The Problem Drugs Don’t Fully Solve
High blood pressure is known as the silent killer because there are often no symptoms until the heart, arteries, and other organs have already been damaged. By the time a diagnosis is made, physical changes to the arterial wall may already be underway.
Hypertension can cause collagen and other material to accumulate in tissue, producing stiff, scar-like areas known as fibrosis. This process affects the walls of blood vessels and organs, including the aorta, the body’s main artery. Arterial hypertension accelerates the stiffening of the aorta that also occurs with normal aging.
Formylpeptide receptors play a critical role in regulating inflammation, an important driver of hypertension-induced end-organ damage. The kidneys bear the brunt of this. Elevated blood pressure damages the glomeruli – the tiny filters responsible for cleaning blood – disrupting filtration and allowing waste products to accumulate. Declining kidney function can then push blood pressure even higher, creating a self-reinforcing cycle.
Current medications are effective at interrupting that cycle at the pressure end. The research team at Monash University and the Baker Heart and Diabetes Institute asked whether it could also be interrupted at the inflammation end, and whether damage already done could be partially reversed.
What Compound17b Actually Does
Formylpeptide receptors (FPRs) sit on immune cells and on cells in the heart and kidneys. When activated, they signal the immune system to stop its inflammatory response and begin tissue repair. The 2026 Communications Biology study found that Compound17b lowers blood pressure, restores vascular function, and reverses renovascular fibrosis in established hypertension by activating these resolution pathways rather than broadly suppressing the immune response.
Conventional anti-inflammatory approaches risk interfering with the immune system’s essential functions, including the ability to fight infection. Compound17b activates the natural inflammation-resolution pathways that should be stopping the immune system from overreacting in the first place, rather than suppressing the immune system wholesale.
The research team divided 45 male mice aged 12 weeks into four groups: normal mice received either an inactive control solution or Cmpd17b, while hypertensive mice received either the control solution or Cmpd17b. Blood pressure, heart rate, and physical movement were tracked continuously over 28 days. In the final week, ultrasound scans measured heart function, and the heart, kidneys, and blood vessels were examined for signs of fibrosis.
The Compound17b Blood Pressure Findings
Treatment with Cmpd17b produced a 6 mmHg pressure reduction in hypertensive mice, with no significant effect in mice with normal blood pressure — a pattern researchers noted could indicate the compound acts selectively when pressure is abnormally high rather than reducing it across the board. That selective action, if it holds up in human trials, would reduce the risk of pushing blood pressure too low – one of the main hazards when managing hypertension.
The pressure effect built gradually, with no sudden drop after the drug was given, and was strongest during the mice’s active period, when blood pressure naturally peaked. This timing is consistent with an anti-inflammatory mechanism operating through the body’s own circadian rhythms rather than directly overriding vessel tone or nerve activity.
The treatment reduced kidney scarring and lowered collagen buildup in the aorta and left ventricle of the heart, with the strongest tissue-repair effects in the kidneys.
A healthy aorta expands slightly with each heartbeat to absorb the shock of blood being pushed out of the heart. When its walls thicken and stiffen, that buffering capacity drops and the heart must work harder to compensate. After 28 days of treatment, aorta flexibility and thickness improvements reached approximately 37% greater flexibility and 22% reduced wall thickness – a degree of reversal that standard antihypertensive medications have not demonstrated in comparable models.
Where the Treatment Fell Short
The drug did not improve heart pumping performance or fully restore function in the smaller blood vessels. The large artery responded, but the network of smaller vessels that carry blood to tissue throughout the body showed little improvement.
The heart’s pumping function, measured by how well the left ventricle contracts, also did not improve significantly during the study period. This suggests that different types of hypertensive damage have different timelines and respond differently to treatment. Fibrosis in a large artery may be more reversible than contractile dysfunction in the heart muscle.
Compound17b was previously shown to attenuate hypertension and adverse cardiovascular remodeling in mice, so this is not its first promising result. But the neurogenic hypertension model used in the 2026 study – where blood pressure is driven primarily by overactivity in the autonomic nervous system – is a different context, and the mixed results show the compound does not resolve all dimensions of the disease.
The study also used only male mice and ran for just 28 days. Human hypertension is far more varied, involving factors like genetics, age, kidney disease, obesity, hormonal changes, and medication interactions. A compound that performs well in a single animal model may behave very differently across a broader population.
Read More: Your Blood Pressure Reading Hides a Third Number That Could Predict Dementia
What This Means for You
Compound17b is not approaching pharmacy shelves. Larger animal studies and human clinical trials will be necessary to establish its safety, effective dose, and true clinical value. This research represents a proof of concept, not a treatment option, and is not a reason to change or discontinue current blood pressure medications.
According to the WHO, an estimated 1.4 billion adults aged 30 to 79 worldwide had hypertension in 2024 – and roughly 600 million of them are unaware they have it. Chronic inflammation can gradually damage blood vessels and organs, and the current emphasis on controlling pressure alone may be leaving a significant part of the disease unaddressed. If future research confirms that the inflammation-resolution pathway is a viable drug target in humans, the goal of hypertension treatment could shift from managing a number to actively repairing the damage that number causes.
For now, the most evidence-backed steps remain the same: work with a physician to find a medication or combination of medications that keeps blood pressure in a healthy range, monitor kidney function regularly if you have longstanding hypertension, and address lifestyle factors that worsen arterial stiffness, including physical inactivity, high sodium intake, and smoking. The Compound17b findings offer reason for cautious optimism about where hypertension science is heading – but how far the results translate from a mouse model to a human patient will take years of rigorous testing to establish.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: The Exact Amount of Nuts You Should Eat Per Day to Help Lower Blood Pressure